Wiley, one of the world’s largest publishers and a global leader in research and learning, announced the 2025 release of the <a target="_blank" rel="noopener noreferrer" href="https://gcms.labrulez.com/products/940">Mass Spectra of Designer Drugs</a>.This database is a critical asset for forensic laboratories around the globe, facilitating rapid identification of illicit substances. Compiled from both legal and underground sources, it offers access to the latest novel psychoactive substances (NPS) like variants of fentanyl, xylazine, various opioids, synthetic cannabinoids, and more.Annually updated, this GC-MS database provides access to 36,360 spectra, representing 27,500 unique chemical entities, along with detailed information and chemical structures.&nbsp;<blockquote>This year’s update introduces over 1,260 new spectra and over 780 unique compounds in major categories of interest.</blockquote>“Forensic laboratories require up-to-date databases to stay ahead of emerging NPS trends. This resource remains crucial in the ongoing battle against drugs.” said Graeme Whitley, director, data science solutions at Wiley.The Mass Spectra of Designer Drugs database is compatible with most major mass spectrometry data systems. Additionally, it is available as a KnowItAll subscription, integrating with Wiley's KnowItAll spectral analysis software, which features automated non-targeted analysis, including feature detection, automatic deconvolution, and library search in a single touch. It also includes tools for identifying novel compounds, such as drug classification models and a patented MS Adaptive Search tool that provides tremendous insight into structural possibilities when there is no exact match.<blockquote>Learn more <a target="_blank" rel="noopener noreferrer" href="https://sciencesolutions.wiley.com/solutions/technique/gc-ms/mass-spectra-of-designer-drugs/">HERE</a></blockquote><h4>About Wiley</h4>Wiley (NYSE: WLY) is one of the world’s largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today’s biggest obstacles into tomorrow’s brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at <a target="_blank" rel="noopener noreferrer" href="https://www.wiley.com/en-ie">Wiley.com</a>.&nbsp;

Wiley releases Mass Spectra of Designer Drugs 2025 – an essential resource for forensic laboratories

Wiley, a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation and learning, today announced the 2026 release of Mass Spectra of Designer Drugs, the essential GC‑MS spectral database used by forensic laboratories worldwide for the rapid identification of illicit substances.As the landscape of novel psychoactive substances (NPS) continues to evolve—with growing numbers of synthetic cannabinoids, metabolites, fentanyl analogs, pharmaceutical drugs and metabolites, derivatives, and other emerging compounds—laboratories rely on continuously updated reference data to keep pace.The latest release includes updates to ensure comprehensive and up‑to‑date support for forensic, toxicology, and drug surveillance workflows:<ul><li>Addition of over 700 new mass spectra</li><li>More than 400 new unique compounds, spanning key NPS categories such as fentanyl variants, xylazine, synthetic opioids including nitazene opioids, and cannabinoids</li><li>37,075 total mass spectra and 27,900 unique chemical entities now represented in the database.</li></ul>“The 2026 release strengthens Wiley’s position as the leading source of trusted spectral intelligence, giving laboratories the high-quality data they need to quickly and confidently identify emerging designer drugs with confidence. These enhancements directly support forensic and public health efforts as new harmful substances continue to appear.” said Graeme Whitley, Senior Director, Data Science Solutions at Wiley.<h4>Purpose‑built for forensic and analytical laboratories</h4>Engineered for the unique demands of forensic and toxicology labs, the Mass Spectra of Designer Drugs database works with most major mass-spectrometry systems and is also available as a KnowItAll database subscription. When paired with Wiley’s KnowItAll software, the database unlocks a powerful suite of advanced forensic tools, including drug classification models and Wiley’s patented MS Adaptive Search, that accelerate the identification and interpretation of both known and emerging compounds. These capabilities empower analysts to detect even novel or unusual substances with greater speed, clarity, and certainty, reinforcing the database’s role as an indispensable resource for laboratories working at the front lines of drug detection.<h5>About <a target="_blank" rel="noopener noreferrer" href="https://www.wiley.com/en-ie/">Wiley</a></h5>Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&amp;D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning.&nbsp;

New release Wiley's Mass Spectra of Designer Drugs 2026 expands coverage of emerging novel psychoactive substances

Article

Product

Events

Webinars

Application

Academy

Video

Poster

Scientists

Plastics

Environment

Food

Water

Health

Presentation

Scientific article

Interview

Toxicology

Popularization

Science and research

Software

Covid-19

Career

Laboratories

Various

Zaměření

Type of News

Focus

For over 200 years we have been helping people and organizations develop the skills and knowledge they need to succeed.
We develop digital education, learning, assessment, and certification solutions to help universities, businesses, and individuals move between education and employment and achieve their ambitions.

Wiley

European Symposium on Analytical Spectrometry (ESAS) 2026

Bruker at the 7th European Symposium on Single Cell Proteomics

Shimadzu at 2026 AOAC Annual Meeting & Exposition

ICP-MS for Hybrid Photoelectrode Characterization

Modern Methods for Faster Microbial Analysis

Addressing LC Method Optimization - Scaling For Efficiency, Throughput And Reproducibility